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1. Introduction
Tumor microenvironment is a dynamic concept that includes, beside tumor cells, everything
is not tumor cells. It consists of cells, soluble factors, signaling molecules, extracellular matrix
(ECM), and mechanical cues that can promote neoplastic transformation, support tumor
growth and invasion, protect the tumor from host immunity and foster therapeutic resistance
[1]. It is organ-specific and in the brain it is not yet fully understood. In addition to cancer cells,
it contains different stromal cells mainly represented by endothelial cells, microglia/macro‐
phages, and reactive astrocytes [2], but other cell types should be considered such as fibro‐
blasts, pericytes, immune cells, etc. (Figure 1). These cells are heterogeneously distributed in
the tumor, according to its different phenotypes and relevant biological significances.
2. Microenvironment cell components
2.1. Microglia/macrophages
Malignant gliomas are rich in microglia/macrophages that are classified as ramified or resident
microglia, ameboid or activated microglia, macrophages and perivascular microglia [3]. They
are called tumor-associated macrophages (TAM) and lack apparent phagocytic activity
[4].They are considered as both intrinsic to the central nervous system (CNS) and blood-borne
arrived, subjected to the local production of chemoattractant factors [5]; they share surface
markers [6], but it has been demonstrated that microglia are chemokine (C-X3-C motif)
receptor 1 (CX3CR1)+/chemokine (C-C motif) receptor 2 (CCR2)– and monocytes are CCR2+/
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CX3CR1– [7]. In acute conditions microglia is blood-derived, from adult haematopoietic stem
cells (HSCs), even though macrophages in adult renew independently from HSCs. Their
majority derives from Tie2+ pathway generating eritro-myeloid progenitors, distinct from
HSCs, from the yolk sac they migrate in the various organs [8].
It is still debated whether they are included in or they are distinct from pro-inflammatory cells.
They increase both in the center and at the periphery of the tumors [9] and it has been calculated
that up to one third of the cells in glioma biopsies are represented by macrophages [9,10]
(Figure 2A,B). In the tissue, microglia/macrophages are found as small or large clusters around
vessels or necroses, whereas at the periphery or around the tumor they are more regularly
distributed. Undoubtedly, they proliferate in response to tumor growth and they have a
cytotoxic defense function [11], as well as the capacity for antigen presentation [12], but they
can also promote tumor infiltration and proliferation [13,14]. An inverse correlation between
TAM infiltration and glioblastoma multiforme (GBM) prognosis [15] and promotion of tumor
progression have been found [16].
Together with fibroblasts, pericytes, neutrophils, mast cells, lymphocytes, dendritic and
endothelial cells, macrophages belong to the category of stromal cells that interact with the
tumor, as discussed before, via cell-cell or by cytokine or chemokine-mediated signaling.
Tumor cells may influence stromal cells to produce growth factors such as vascular endothelial
growth factor (VEGF), tumor necrosis factor alpha (TNF-α), transforming growth factor beta
(TGF-β), interleukin 1 (IL-1) or CXC ligand 2 (CXCL2), CXCL8, CXCL12 that promote angio‐
genesis and tumor growth. Conversely, tumor cells are stimulated to produce chemokines that
influence angiogenesis [16] and growth. There is both an autocrine and a paracrine tumor
Figure 1. Scheme of the relationship between vessels/endothelium and microenvironment cells.
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growth stimulation [17]. The enrichment in stromal cells, especially microglia/macrophages,
in the brain adjacent to tumor (BAT) strongly influences immunoregulation and tumor growth
on the one side, and it represents a defense from the tumor on the other side.
The existence of a positive relationship between microglia/macrophages and tumor-initiating
cells (TICs) in the two opposite directions is relevant to the problem [18]. The vessels can be
associated or not with macrophages (Figure 2C,D) even with only one (Figure 2E). They occur
obviously in circumscribed necroses (Figure 2F). Basically, any glioma-associated monocytic
cell with macrophage characteristics has been called “tumor associated microglia”. It shows a
functional phenotype different from the inflammatory one and promotes glioma cell migration
and tumor growth [19]. Migration promotion is accomplished through matrix metalloprotei‐
nases (MMPs) released by microglia [20,21] and CX3CL1 with its receptor (CX3CR1) [22]. The
demonstration that microglia/macrophages promote glioma progression means that their
inhibition can be a useful therapeutic tool [23]. Macrophages have long been recognized as
critical components of immunity against tumors, because, when appropriately stimulated,
they can attack tumor cells by contact interaction or by secreting cytotoxic and cytostatic factors
[24]. However, they can also contribute to tumor development, by secretion of growth factors
such as angiogenic factors, proteinases, which degrade the matrix, and immunosuppressor
factors [25]. Their dual function is mainly exerted through TNF that demonstrates both an
anticancer [26] and a tumorigenic activity [27]. However, it has also been shown that TNF can
reduce glioma growth and prolong patient survival [28].
One specific question is the role of immune cells in the tumor microenvironment. These cells
through cytokines, growth factors, chemokines and cerebrospinal fluid (CSF) interfere with
tumor initiation, angiogenesis, proliferation and invasion [29]. IL-1β is the primary factor of
microglia that enhances TGF-β, that, in turn, inhibits lymphocyte proliferation by suppressing
antiglioma responses [30]. IL-1β also stimulates VEGF, epidermal growth factor receptor
(EGFR) and MMP9 for angiogenesis, proliferation and invasion [31].
Macrophages can be subdivided into M1 and M2 subtypes, according their polarization status,
supporting tumor suppression or progression, respectively [32]. As shown by the marker
MHCII [33], they are strongly M2 in GBM [34]. In summary, it can be stated that macrophages
support tumor progression and that tumor recruit macrophages [35]. There is an interrela‐
tionship between glioma stem cells (GSCs) and TAMs in GBM and it was shown that the former
express Periostin, a member of the Fasciclin family (POSTN) [36] that has a supportive role in
various tumors. TAM density correlates with POSTN in GBM and disrupting it TAM density
is reduced so that GSCs secrete POSTN to recruit M2 that support tumor growth [37]. It was
then showed that POSTN is highly expressed in high grade in comparison with low grade
tumors [38]. How POSTN acts in potentiating tumor progression in niches has been widely
discussed [39].
2.2. Reactive astrocytes
Reactive astrocytes can be sometimes confused with tumor cells, mainly because their
phenotype changes over time until their complete maturation. There are analogies between
glial reaction and physiological maturation of astrocytes during embryogenesis. In the initial
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phases, the fine processes originate directly from the cell soma and then from the thick and
long processes [40]. Nestin and Vimentin would be the main markers of immature astrocytes
whereas glial fibrillary acidic protein (GFAP) is the main marker of mature astrocytes [41,42].
Figure 2. Glioblastoma. Macrophages/microglia. A – Cluster of macrophages in a proliferating area, not in relation
with vessels; x200. B – Regular distribution of macrophages/microglia in a proliferating area not in relation with ves‐
sels; x200. C – Cluster of macrophages around a middle size vessel; x400. D – One vessel is surrounded by a crowd of
macrophages, the other has none; x200. E – Capillaries with a macrophage adherent to the wall; x200. F – Macrophages
in a perinecrotic palisade; x400. All double staining CD68-CD34, Alkaline Phosphatase Red and DAB, respectively.
It is still a debated question whether tumor infiltration can be recognized by magnetic
resonance imaging (MRI), not only when adjacent to tumor, but also at distance. It has been
observed, for example, that low grade gliomas, which preferentially locate in the insula and in
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the supplementary motor area, spread along distinct subcortical fasciculi [43]. By analyzing
different peritumor areas with different MRI methods, it has been shown that fractional
anisotropy and not apparent diffusion coefficient can be used to evaluate glioma cell invasion.
An attempt to classify different peritumoral tissues by a voxel-wise analytical solution using
serial diffusion MRI has been made [44].
Figure 3. Glioblastoma. Reactive astrocytes. A – Regular distribution of reactive astrocytes in a cortex with mild infil‐
tration. Some adhere to small vessels; GFAP, x200, DAB. B – Proliferating area with reactive astrocytes entrapped; al‐
most only the large cytoplasm is visible; GFAP, x200, DAB. C – Glomeruli: multi-channel formations; double staining
CD68-CD34, x100, DAB and Alkaline Phosphatase Red, respectively; D – Microvascular proliferations; x200, H&E. E –
Pericytes; α-SMA, x200, DAB. F – Id. x400.
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Peritumoral reactive gliosis (Figure 3A) has a particular importance because of three main
characteristics: reactive astrocytes divide by mitosis as tumor cells do, they progressively lose
Nestin and increase GFAP expression, as during development, and they may regionally exert
a series of metabolic and molecular influences [45]. The most important point is that reactive
astrocytes may be included in the advancing tumor (Figure 3B), in which they progressively
become no more recognizable from tumor cells. The question is whether they disappear
suffocated by the high tumor cell density, or if they remain, unrecognizable from tumor cells,
to contribute to the pleomorphic aspect of gliomas, or if they even can be transformed into
tumor cells [46]. There are evidences that reactive astrocytes support tumor progression [2].
3. The glioma origin and the stem cell theory
The existence of a similarity between cancer cells and embryonic stem cells is known since
Virchow [47]. Glioma cells may derive through tumor transformation from immature glia cells
[48,49], or primitive neuroepithelial cells or neural stem cells (NSCs) and many experimental
demonstrations are available on this matter [50,51]. Glioma-initiating cells (GICs) and GSCs
[52,53] share with NSCs some properties, i.e. proliferation and self-renewal, and GSCs share
with malignant gliomas similar genetic alterations. In contrast to the hypothesis of the
transformation of NSCs or neural progenitor cells (NPCs) into GSCs [54], either occurring in
situ during embryogenesis or during migration and their relationship with GICs, the origin of
GSCs has also been referred to dedifferentiation.
Dedifferentiation may refer to two distinct biological processes. The first one is represented
by a multi-step process accompanied by genetic alterations that lead to the progressive
transformation of normal cells into highly malignant cells. They require self-sufficiency growth
signal, insensitivity to anti-growth signals, escape from apoptosis, proliferation potential,
angiogenesis and invasion [55]. By combining activation of specific oncogenes and loss of
tumor suppressor genes, it is possible to induce GBM from cortical astrocytes [56]. Examples
are the combination of p16(INK4a)-p19(ARF) loss with K-Ras and Akt activation [57],
p16(INK4a) and p19(ARF) loss with EGFR activation [58] and p53 loss with myr-Akt and c-
Myc overexpression in mature astrocytes [59]. Basically, the capacity of transformation
inversely correlates with differentiation. It is easier to get transformation from Nestin+
progenitors than from mature astrocytes by Ras and Akt activation [60].
A second meaning of dedifferentiation refers to tumor cells that would acquire stemness
properties instead of reflecting the nature of the primitive cells [50,61].
Today, the existence of cell subpopulations, called cancer stem cells (CSCs) or GSCs, with stem
cell-like properties such as multipotency, ability to self-renewal or to form neurospheres in
vitro, is generally accepted, also for gliomas [62].
The origin of gliomas from NSCs has been repeatedly demonstrated by the experimental
induction of brain tumors by nitrosourea derivatives [63]. Moreover, NSCs have been accepted
as the source of gliomas, also because the signaling that regulates their self-renewal, prolifer‐
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ation and differentiation occurs, altered, in gliomas. Several studies demonstrated that GBM
may arise from the subventricular zone (SVZ) [64,65] that is the source of stem cells and
progenitors in adults [66,67]. The latter are represented by neuroblasts (type A cells) and
oligodendrocyte precursor cells (OPCs), by quiescent type B cells that give origin to highly
proliferative cells, and by transit-amplifying progenitor cells (type C cells), that differentiate
into two lineage-restricted progenitor cells [68,69]. These cells accumulate mutations up to give
rise to gliomas [70], not excluding the intervention of human Cytomegalovirus (HCMV) [71].
GBM is a heterogeneous tumor and its heterogeneity might be explained by either the
hierarchical model mechanism [72] or the stochastic mechanism of development [73]. Progen‐
itor cells are at risk of malignant transformation since they show the activation of the adequate
cell machinery, represented by telomerase activity, promitotic and antiapoptotic genes [54].
Abnormal developmental patterns are Sonic hedgehog (Shh) pathway, EGFR and phosphatase
and tensin homologue (PTEN) signaling. Although their clonal origin is from a small fraction
of transformed NSCs, gliomas are heterogeneous as a consequence of an anomalous tumor cell
differentiation [74]. The diversity within gliomas is due to changes of the subclones, being all
of them generated by multipotent tumor cells, but also through an arrest of the differentiation
process.
Recently, other cells have been supposed to give origin to GBM.
4. Origin of GSCs and glioma heterogeneity
The hypothesis of GSCs is based on the concept that a rare subset of cells within GBM may
have  significant  expansion  capacity  and  the  ability  to  generate  new  tumors  [72].  The
remainder  of  tumor cells,  which predominantly  resemble  GBM, may represent  partially
differentiated  cells  with  limited  progenitor  capacity  or  terminally  differentiated  non-
tumorigenic cells.  A possible origin of gliomas is also from mature astrocytes by acquir‐
ing stemness properties through a dedifferentiation process, as above mentioned [54,75] or
from NG2 cells that fit  better with tumors arising far from the ventricles or with secon‐
dary GBMs [76]. Also reactive astrocytes can be candidate for gliomas [77,78], since they
can acquire a stem-like phenotype [79].
In spite of the great similarity between SVZ NSCs or progenitors and GICs, the relationship
with GSCs remains unresolved. Are they equivalent, or the latter have nothing to share with
the former, if not the stemness properties? An answer can be that over time GICs can acquire
sufficient alterations to engender GSCs. GICs are the first genetically aberrant cells that can
initiate tumor development and that are responsible for the bulk of tumor cells. OPCs, the
major dividing cell population in the adult brain that gives origin to oligodendrocytes,
distributed in the SVZ and in the gray and white matter, remain a further unresolved problem.
The EGFR and prostaglandin-endoperoxide synthase 2 (PTGS2) inhibition prevents the
tumorigenesis of transformed OPCs and GICs for anaplastic oligodendroglioma but not the
tumorigenesis of transformed NSCs or GICs for GBM, suggesting that the latter can arise from
OPCs or NSCs [80].
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In mice models, by using the retrovirus replication-competent avian sarcoma-leukosis virus
long terminal repeat with splice acceptor (RCAS) [81], OPCs expressing 2’, 3’-cyclic-nucleotide
3’-phosphodiesterase (CNP) could be targeted later in their development or in the adult. Low
grade oligodendrogliomas were obtained by RCAS-platelet-derived growth factor subunit
beta (PDGF-β) expressing OPC markers such as sex-determining region Y (SRY)-box2 (SOX2),
oligodendrocyte transcription factor 2 (OLIG2), NG2 and PDGF receptor (PDGFR), interpreted
as indicating a slight dedifferentiation of tumor cells [82]. OPCs could serve as cells of origin
of gliomas [83]. According to the already mentioned experiments by mosaic analysis with
double markers (MADM), aberrant growth of precancerous lesions could only be found in
cells differentiated along the oligodendrocyte lineage to become OPCs but not in any other
lineage or in NSCs [84]. These demonstrations, however, do not exclude that aberrant growth
can occur in NSCs, responsible for a direct origin of malignant tumors.
Heterogeneity in gliomas is not due to the occurrence in the same tumor of different non-tumor
cells of various species, but to the cellular complexity formed by tumor cells that differ among
themselves for a series of phenotypic and molecular characteristics affecting cell proliferation,
invasion, etc. [85,86]. Cells are at risk of transformation only when demanded to proliferate,
such as progenitors, opposite, for example, to B cells of SVZ that are protected [87]. The passage
from B cells to amplifying cells implies a chromatin rearrangement from a quiescent to a
proliferating status where genetic lesions, if not repaired, pass to the following dividing cells.
There are interactions among DNA repair, epigenetics and stem cells. In the niche a homeo‐
static regulation of stem cells occurs, with a balance between self-renewal and differentiation,
and with proliferation starting in response to a stimulating signal. Uncontrolled proliferation
would take place when stem cells become independent of growth signal, because of mutations,
or they resist anti-growth signals [88]. The homeostatic balance would be regulated by the
interaction between Wnt/β-catenin pathway, that promotes cell growth, and bone morphoge‐
netic protein (BMP) signaling that inhibits it. This can be the starting point of heterogeneity,
largely dependent on the microenvironment. Gliomas with different genetic signatures may
as well originate from different cell subtypes [89].
The same molecular mechanisms of NSCs regulate gliomas [90] that can undergo epigenetic
changes and genetic mutations favoring evolution toward malignancy. During their lifespan,
they can be exposed to genotoxic stress, to which they respond through repair mechanisms
[76]. GBM has many molecular signatures depending on its polyclonality, and the events
themselves may have an effect on the clonality. The greater is the potency of stem cells, the
more anaplastic is the tumor.
The molecular profile of malignant gliomas has led to the distinction of proneural, proliferative
and mesenchymal types associated to NSC profiles [91] or to the distinction of proneural,
classic and mesenchymal types, the former expressing genes associated to progenitors and the
latter two to stem cells [92]. The stemness would reflect the cell of origin, but it could also be
acquired in the niche in adult gliomas [93]. On this basis, the contrasting results obtained on
GBM can be explained by the finding of different series of TICs characterized by different
phenotypic and molecular profiles [86,94].
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5. Migration of NSCs or NPCs toward tumors
NPCs can migrate from the SVZ toward a tumor and target it [95]. Today, this migration
may represent a new goal for therapeutic purposes. NSCs exhibit tumor-homing capabili‐
ty. In mice experiments, immortalized murine NSCs, implanted into glioma-bearing rodents,
distributed within and around tumors, even migrating to the contralateral hemisphere [96].
Genetically engineered NSCs show a tropism for gliomas, on which may have an adverse
effect [97-100], especially if they are also transduced with herpes simplex virus-thymidine
kinase (HSVtk) gene and followed by the administration of systemic Ganciclovir [101-103].
Human NSCs implanted in rat brains containing a C6 glioma, migrated in the direction of
the expanding tumor [104].  The same properties  are  shown by mesenchymal  stem cells
(MSCs) injected either into carotid arteries or intracerebrally [105,106] and by hematopoiet‐
ic progenitor cells [107]. Endogeneous progenitor cells have been observed to migrate from
the SVZ toward a murine experimental GBM [108]. The migrated Nestin+ cells were also
actively cycling,  as  shown by Ki-67/MIB.1 positivity,  and 35% of  them expressed Musa‐
shi-1 [109]. In transgenic mice, virally labeled proliferating cells of the SVZ demonstrated
that  NPCs  accumulate  around  gliomas,  diverted  from  their  physiological  migratory
pathway to the olfactory bulb [110].
Chemokines, angiogenic cytokines and glioma-produced ECM can play a role in the NSC
tropism [111].  It  is  possible  to  take  advantage of  the  natural  capacity  of  chemokines  to
initiate migratory responses and to use this ability to enhance the tumor inhibitory capacity
by  NPCs  to  target  an  intracranially  growing  glioma  [112].  The  therapeutic  possibilities
offered  by  NSCs  are  continuously  increasing.  For  example,  they  can  be  engineered  as
sources of secreted therapeutics, exploiting their mobility toward CNS lesions. They could
function as minipumps [113].
Rat embryonic progenitor cells, transplanted at distance from a glioma grown in the striatum,
migrate and co-localize with it. They modify their phenotype, express Vimentin and reduce
the tumor volume, demonstrating that a cross-talk exists between them and the tumor [114].
It has been shown that hypoxia is a key factor in determining NSC tropism to glioma by
stromal-derived factor 1 (SDF-1) and its receptor (CXCR4), urokinase-type plasminogen
activator (uPA) and its receptor (uPAR) and VEGF and its receptor (VEGFR) [115]. It could be
interesting to try to enhance motility of adult NSCs toward CNS injury or disease and to take
into account that EGFR could play a role, because of its participation to malignant transfor‐
mation [116]. It has also been recognized that a limitation exists to the possibility of migration
of neural precursors from SVZ to an induced cortical GBM in mice. The limitation is caused
by the age and the proliferation potential of the SVZ. Adult mice supply fewer cells than
younger mice, depending on the expression of D-type Cyclins, because with aging Cyclin D1
is lost and only Cyclin D2 is expressed [110]. Recently, novel treatment strategies using NSCs
have been proposed, for example the suicide gene therapy using converting enzymes [117].
New strategies will emerge from further NSC and brain tumor stem cell (BTSC) studies [118].
Is it possible that tumors grow from transplanted NSCs [119]?
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6. Perivascular niches (PVN). Relationship between NPCs/GSCs and
endothelial cells
GBM is composed of three concentric zones: a central necrotic area, surrounded by an
intermediate zone containing large vessels with thrombosis or altered walls; a surrounding
proliferation zone that abruptly or progressively flows into the normal tissue and invades it
[63]. Neo-angiogenesis takes place in the proliferating zone or in normal surrounding tissue
after tumor cell invasion. In the latter, new capillaries are formed from the pre-existing venules.
Basically, new capillary formation is due to the endothelial proliferation that mimics angio‐
genesis in normal embryonic conditions, with buds and new tubule formation. In comparison
with normal angiogenesis, tumor angiogenesis is often dysregulated until the formation of
glomeruli (Figure 3C). In the invasion zone, tumor cells wrap around vessels (co-option). In
invaded cortex, the vascular tree coming down from the meningeal vessels is assailed by
advancing and invading tumor cells and it progressively deforms through endothelial cell
hypertrophy and hyperplasia. It becomes less adequate to perfuse the increased mass of tumor
cells coming up from the white matter, because transformed into a lumpy tree with irregular
lumina. The generated microvascular proliferations (MVPs) (Figure 3D) are mainly found at
the transition from central necrosis to the proliferation zone, where circumscribed necroses
with pseudopalisading develop [120]. As a consequence, areas very rich in capillaries and small
vessels, produced by an intense angiogenesis, coexist in tumors beside areas poorly vascular‐
ized where necroses develop.
Vasculogenesis is a mechanism of tumor neovascularization that has been also attributed
to circulating bone marrow (BM)-derived cells known as endothelial progenitor cells (EPCs).
Its importance is debated [121,122], but it was shown that mesenchymal progenitors from
bone  marrow  can  differentiate  into  proliferating  endothelial  cells  [123,124].  Also  BM-
derived TAMs, including TIE-2 expressing monocytes/macrophages (TEMs), circulate in the
blood, home at sites of pathological neovascularization and differentiate into endothelial
cells or macrophages [125,126].
Another type of vascularization is represented by the “vascular mimicry” due to the capacity
of tumor cells to form a functional net of channels coated by themeselves. Two types of vascular
mimicry have been described. The patterned matrix type is composed of a basement mem‐
brane, lined by tumor cells, forming channels with flowing blood [127]. Vasculogenic mimicry
of the tubular type may be morphologically confused with endothelial cell-lined blood vessels.
In both types, cells express endothelium-associated genes, as in embryonic vasculogenesis
[128,129]. These properties are associated with CSCs [130]. By fluorescent in situ hybridization
(FISH) and immunophenotyping, these non-endothelial cell-lined vessels have been demon‐
strated to be primary tumor cells. In vitro CD133+ GSCs are vasculogenetic even with vascular
smooth muscle-like cell differentiation. The cells do not express CD34 and show EGFR gene
amplification [131]. It must be remarked, however, that usually cells of tumor vessels and
MVPs never show either isocitrate dehydrogenase 1 and 2 (IDH1/2) mutations or EGFR gene
amplification, never exceeding 1 or 2 copies [132]. They do not share with tumor cells genetic
alterations and this is in line with the lack of TP53 mutations in MVPs [133].
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In tumors transplanted into mice and irradiated, recruitment through hypoxia of BM-derived
cells occurs, able to restore circulation through SDF1 and CXCR4 [134]; among these cells, EPCs
prevail [121,135-137]. Vasculogenesis can be blocked by pharmacological inhibition or
antibodies toward SDF1 and CXCR4 [134].
Interestingly, also a GBM-endothelial cell transdifferentiation is considered to contribute to
tumor vascularization, favored by hypoxia [138], independently of VEGF [139]. It has been
observed that a quota of GBM CD31+ endothelial cells shares with tumors cells chromosomal
aberrations [140] and that a quota of GBM CD105+ endothelial cells harbours the same somatic
mutations identified within tumor cells, such as amplification of EGFR and chromosome 7
[141]. In a GBM model, it was demonstrated that the tumor-derived endothelial cells originated
from TICs [138]. This finding is of paramount importance because of the possibility to use an
anti-VEGF antibody (Bevacizumab) for therapy [142]. Unfortunately, the effects of the drug
are only transient [143] and the reason of the failure is the activation of other pro-angiogenic
pathways, the recruitment of BM-derived cells and the increase of pericyte protection and
tumor invasion [144,145]. The possibility that the tumor becomes more aggressive after therapy
has been contemplated [146].
The problem of transdifferentiation and the role that CSCs play in this process are still under
discussion [139]. All the observations have been made in animals or from animal models, and
in vivo experiments of transdifferentiation have been challenged [85]. In human pathology, the
contribution of tumor cells to the GBM vasculature has never been demonstrated and vessel
cells with typical genetic changes of tumor cells, such as those of EGFR, PDGFR, PTEN, TP53,
IDH1/2 have never been found in GBM [132].
By intussusception, pre-existing brain capillaries can be multiplied by transluminal endothelial
bridges and by lumen partitioning; it is an early phenomenon [147].
As NPCs or NSCs reside in the normal SVZ niche at close contact with endothelial cells, in
GBM, GSCs and/or NPCs are located in PVN. In the latter, a strict similarity exists with what
happens in the normal SVZ niche, where the intimate association between normal NSCs and
endothelial cells regulates self-renewal and differentiation of the former. In PVN, angiogenesis
is activated by VEGF produced by NSCs/GSCs [88,148], whereas their stemness is maintained
by Notch produced by endothelial cells through nitric oxide [19,149,150]. Notch is constitu‐
tively active in high grade gliomas and conditions their progression [104]. PVNs are strictly
correlated with tumor progression. There would be a bidirectional communication between
endothelial cells and TICs or GSCs [151].
The PVN composition has been carefully described in GBM, with the inclusion, beside cells of
the environment, of ECM, integrins, cell adhesion signaling, cadherin family, etc. [152]. In
GBMs, strong evidence for the existence of an endothelial mesenchymal transition (EMT)
process is still lacking, but this process is increasingly reported as instrumental to tumor
growth and diffusion [153,154]. It is defined by the possibility that differentiated epithelial
cells establish stable contacts with neighbor cells, assume a mesenchymal cell phenotype with
loss of cell-cell interactions, reduce cellular adhesion, active production of ECM proteases,
increase cytoskeletal dynamics and changes in transcription factor expression, and acquire a
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stem cell program, all of them leading to increased migration and invasion ability [155]. The
three major groups of transcription factors, the SNAI, Twist-related protein 1 (TWIST1) and
Zinc-finger enhancer binding (ZEB) family members, have been reported to be altered in GBM.
Their over-expression follows the activation of Wnt/β-catenin pathway and results in vitro in
an increased cell migration and invasion [156,157]. It is likely that the high expression of
mesenchymal genes in the mesenchymal subset of human GBMs [91] can be considered to be
reminiscent of the EMT program [92] or that the aberrant activation of EMT factors during
gliomagenesis can trigger the mesenchymal shift in GBM [158].
The influence that GSCs can exert on BM-derived endothelial cells has been summarized as
follows [159]: to elicit angiogenesis, to home at the tumor the BM-derived EPCs and to promote
their differentiation into blood vessels that incorporate into the existing vasculature. Trans‐
differentiation into endothelial-like cells contributes to the formation of blood vessels [140,160].
The PVN concept was substantiated by the demonstration of Nestin+ and CD133+ cells on
capillaries, forming a microvasculature in which the microenvironment that maintains CSCs
and their renewal is given by endothelial cells that, in turn, are stimulated by CSCs [149]. A
positive correlation was found between the CD133+ niches and CD133+ blood vessels, similar
to the correlation between the Nestin+ niches and Nestin+ blood vessels [161]. A good PVN
demonstration has been given [2] and beautiful and useful schemes have been provided [159,
162]. It can be added that angiogenesis and self-renewal would represent a resistance to chemo-
and radio-therapy.
The location of GSCs in PVN was confirmed by several studies using either CD133 positivity
[163] or side population signature genes, such as aspartate beta-hydroxylase domain-contain‐
ing protein 2 (ASPHD2) or nuclear factor erythroid 2-related factor 2 (NFE2L2) or hypoxia-
inducible factor 2 (HIF-2) [164]; they increase with malignancy [161]. By comparing xenografts
of C6 glioma with a high or low fraction of GSCs, it was observed that the former exhibit an
increased microvessel density and an increased recruitment of BM-derived endothelial
progenitors [123]. The relevance of the hypoxia will be discussed later.
6.1. Pericytes
Pericytes, the last PVN component, are perivascular cells that support blood vessels [165],
control blood vessel stability, function through paracrine factors and direct cell-cell contacts,
and promote vascular maturation (Figure 3E,F). They express different markers including
PDGFR-β, α-smooth muscle Actin (α-SMA), Desmin, and NG2. They originate from meso‐
derm-derived MSCs or from neuroectoderm-derived neural crest cells, depending on their
location within the brain. Pericytes are an essential element of the neurovascular unit and
contribute to the function of blood-brain-barrier (BBB) [166]. Gliomas can induce the differ‐
entiation of MSCs into pericytes [167]. MSCs injected into brain tumors in mouse models have
been shown to closely associate with the tumor vasculature and also with up-regulation of the
expression of pericyte markers [168].
Pathology observations show that pericytes increase in number in GBM and wrap around
vessels with endothelial hyperplasia.
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7. PVN neuropathology
The description of the niches must be obviously a survey of the different vascular structures
in GBM with their surrounding cell components. The first question to give an answer is: does
each vascular structure represent a niche, or are they distributed in the tumor and how? The
second question is: is the cell composition of the niches a constant one or does it vary from one
another? In the literature, GSCs have been demonstrated in perivascular position [149], as well
in perinecrotic niches [164,169] as discussed later. Good schemes of PVN are provided
including all the cells that can be encountered in such position [62,159,162]. Such schemes,
obviously, are not encounted as real occurrences in the histological examination of GBMs.
By examining the vascular structures in the different tumor zones, in infiltration areas
capillaries, arterioles, venules or penetrating vessels from the meninges occur. Around them,
there are tumor stem cells/progenitors, often forming cuffings (co-option), or Nestin+ cells
adherent to the walls, or reactive GFAP+ astrocytes (Figure 4A–D). Scattered in the tissue,
microglia/macrophages occur rather regularly, occasionally distributed in perivascular
position (Figure 2). Reactive astrocytes continue to be present also in more intense infiltration,
recognizable for their GFAP positivity and for what remains of their long and thick processes;
however, they are regularly distributed in the tumor tissue and occasionally they can be found
in perivascular position.
In areas of intense tumor cell proliferation, many small vessels can be found either with or
without endothelial hyperplasia, sometimes forming a dense net. Around them, tumor cells,
mostly Nestin+ and SOX2+, crowded, that can easily be considered as undifferentiated and
containing sometimes cells with stemness properties, associated with occasional CD68+ cells.
In proliferating areas, larger vessels can be found, with walls thicker than in capillaries,
surrounded by a dense cuffing of cells that are Nestin+ in the inner part and GFAP+ outside
(Figure 4E,F). In most vessels, pericytes appear wrapping the channel outside the endothelial
cell layer; they are well evident in MVPs or in glomeruli that, on the other hand, do not appear
to be surrounded by other cell types, if not tumor cells.
In intermediate areas or near the central necrosis, many vessels of different size and nature are
associated with edema or tissue dissociation and they do not show to be surrounded by any
special cell kind. Scattered in the tumor, myeloid cells can be found in variable quantity,
associated or not with other types of cells among which macrophages seem to be the most
frequent. Microglia/macrophages are distributed in small or large clusters around necroses or
around vessels where they can be associated or not with some of the other cell types. The
association with myeloid cells is the most striking.
The neuropathological study provides the information that PVN represents a theoretical
picture where the different cell types can be represented and where cross-talks occur among
the different signalings that support some tumor activities such as invasion, growth, etc. Of
course, the most important dialogue in these structures occurs between GSCs and endothelial
cells, and this is feasible around capillaries and small vessels, even though the thickness of the
vessel walls could not in absolute be an insuperable obstacle.
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8. Hypoxia and necroses – Perinecrotic niches
In GBM, there are two main types of necrosis: large necroses, usually at the tumor center, of
thrombotic origin, and circumscribed necroses, occurring in the proliferative areas and
representing a hallmark of the tumor. Hypoxia is, therefore, a tumor characteristic [170],
mediated by HIF-1/2 composed of two subunits, an oxygen insensitive HIF-β subunit and an
oxygen regulated HIF-α subunit [171]. Under normoxic conditions, HIF-α is rapidly degraded
following hydroxylation by the oxygen-dependent prolyl-hydroxylase domain proteins
(PHDs), that mark it for ubiquitination and proteasomal degradation [172]. Hypoxia stabilizes
HIF-1α by preventing its hydroxylation and degradation; together with HIF-2α, it is critically
involved in the regulation of GSCs [164]. Hypoxia directly promotes the GSCs expansion. In
human GBM biopsies, GSCs are enriched in perinecrotic regions, where the oxygen tension is
reduced and HIF-1α and HIF-2α are activated [164,173]. HIF-2α remains elevated under
chronic hypoxia, while HIF-1α is only transiently upregulated [174].
Hypoxia through HIF-1α promotes the expansion of GSCs through the phosphatidylinositol
3-kinase (PI3K)/Akt and ERK1/2 pathways, the inhibition of which reduces the fraction of
CD133+ GSCs [175]. In perinecrotic regions hypoxia regulates many properties [159]. In GSCs
under hypoxic conditions, it activates Notch by inducing its ligands and the activation of target
genes Hes1 and Hey2 [164,176]. Blockade of Notch signaling with γ-secretase inhibitors
depletes the GSC population, reduces the expression of GSC markers such as CD133, Nestin,
Bmi1 and OLIG2 and inhibits the growth of tumor neurospheres and xenografts [177].
GSCs can be demonstrated to lie around circumscribed necroses or scattered in the tissue by
CD133 positivity [169] or other specific antigens [164].
Hypoxia is generally realized when tumor growth exceeds neovascularization, and it would
not only regulate tumor cell proliferation, metabolism, differentiation, but also induce key
stem cell genes such as Nanog, Oct4 and c-Myc [178].
Necroses are the place where hypoxia occurs, but it must be taken into account that usually
its occurrence is histologically deduced from its pathologic effects, i.e., necrosis in the tissue.
Hypoxia at its very beginning could not yet be visible as necrosis, but already efficient for other
signs. It is possible that tissue features in an area not suspected to be hypoxic, are indeed due
to hypoxia. An example is given by apoptosis. Apoptotic nuclei are found in proliferating
tumor areas due to an intrinsic or transcriptional pathway via mitochondria and focused on
TP53 [179], or in hypoxic areas through an extrinsic pathway or TNF [180].
It is, however, possible that isolated apoptotic nuclei in a proliferating area are not due to the
first type of apoptosis, i.e. the intrinsic one, but to the extrinsic type, consequence of a not yet
morphologically evident hypoxia [181]. As a matter of fact, HIF-1α expression can be mainly
demonstrated around circumscribed necroses, but also in scattered cells in proliferating areas
(Figure 5A,B) [45].
Circumscribed necroses in GBM are the hallmark of the tumor, but their origin and develop‐
ment are still discussed. They have been carefully described and codified [139,182,183] as due
to an ischemic process following a vascular occlusion or to a pathology of the endothelium.
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The consequent hypoxia would stimulate angiogenesis, through HIF-1 and VEGF. Another
interpretation can be given: necroses develop in hyperproliferating areas, with a high Ki-67/
MIB.1 labeling index (LI) and a high Nestin expression in comparison with GFAP, due to the
focal insufficiency of angiogenesis to feed a very large number of tumor cells, because of the
imbalance between the high tumor cell proliferation capacity and the low one of endothelial
cells (Figure 6A–F and Figure 7) [184-186].
Figure 4. Glioblastoma. D – Nestin+ tumor cells adhere to small vessels; Nestin, x200, DAB. B – GFAP+ cells scattered
in the tissue or in relation with vessels directly or by vascular feet: tumor cells or reactive astrocytes; double staining
GFAP-CD34, x200, DAB and Alkaline Phosphatase Red, respectively. C – Id. with a cuffing of GAFP+ cells in the outer
layer; GFAP, x200, DAB. D – Cuffing of Nestin+ cells on a medium size vessel; Nestin, DAB, x200. E – Infiltrative area
with Nestin+ cells on small vessels; Nestin, x200, DAB. F – Id. Some GFAP+ tumor cells adhere to vessels; GFAP, x200,
DAB.
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Figure 5. Glioblastoma. A – HIF-1+ cells in perinecrotic position; HIF-1, x200, DAB. B – HIF-1+ cells scattered in a pro‐
liferative area; HIF-1, x200, DAB. C – A large avascular area; CD34, x25, DAB. D – High vessel density; CD34, x100,
DAB. E – Perinecrotic palisade with high density of SOX2+ cells; SOX2, x200, DAB. F – Cuffing of SOX2+ cells around
vessels; SOX2, x200, DAB.
This observation does not exclude that inside necroses regressive pathological vessels occur
[183]. In GBMs, beside areas with a high vessel density due to an active neoangiogenesis, large
avascular areas occur where necroses develop (Figure 5C,D).
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Figure 6. Glioblastoma. A – High Ki-67/MIB.1 labeling index (LI) in a hyperproliferating area; Ki-67/MIB.1, x200, DAB.
B – High Ki67/MIB.1 LI in the perinecrotic palisade; Ki-67/MIB.1, x200, DAB. C – Perinecrotic palisade with high densi‐
ty of Nestin+ cells; Nestin, x400, DAB. D – Id. with only rare GFAP+ cells; GFAP, x400, DAB. E – A circumscribed ne‐
crosis in hyperproliferating Nestin+ area; Nestin, x200, DAB. F – Id. only rare GFAP+ tumor cells; GFAP, x200, DAB.
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The palisades would be the remnants of the hyperproliferating area after necrosis develop‐
ment. Both are composed of a high number of cells positive for stemness markers such as
CD133, Nestin, SOX2, and RE-1-silencing transcription factor (REST), and have a high
proliferation index (Figure 5E,F) [163,187,188]. GSCs can be conceived as deriving from
dedifferentiated tumor cells that acquired stemness properties [189]; they would be concen‐
trated in the above mentioned malignant tumor areas where circumscribed necroses develop
because of the vascular insufficiency. It is likely that GSCs around necroses represent the quota
of GSCs that populated the hyperproliferating areas and remained unaffected by necrosis
development. The palisadings themselves would be the remnants of hyperproliferating areas,
spared by necrosis [45,189].
Figure 7. Progression from hyperproliferating areas with GSCs/progenitors → development of avascular area → ap‐
pearance of necrosis → necrosis surrounded by GSCs/progenitors.
9. Functions of the niches in the tumor and their interdependence
The GSC maintenance is provided by the signalings that occur in the niches; they can expand
and form new ones that, in turn, drive the tumor growth [190]. Signalings involved in the GSC
regulation are Oct4, c-Myc, Notch, TGF-β, Wnt/β-catenin pathways. Genes associated with
shorter patient survival, as already observed [91], are overexpressed in the side population
found by Seidel et al [164] and, viceversa, downregulated in those associated with longer
survival. The overexpression concerns more primary than secondary glioblastomas that show
a reduced CSC component [191] that, however, may still support tumor growth.
Perivascular and perinecrotic niches are not separated entities, first of all for temporal reasons.
Hypoxia is the main cause of angiogenesis, but this is realized through factors, such as VEGF,
Angiopoietin 1 and 2, SDF1 produced by GSCs and, at the same time, the imbalance between
the high proliferation rate of tumor cells and the low one of endothelial cells makes angiogen‐
esis insufficient and causes necrosis development. Moreover, besides tumor areas rich in small
neo-formed vessels and capillaries, MVPs due to a dysregulated angiogenesis do not show
sufficient exchanges with tumor cells and are responsible for hypoxia [63]. Another important
question, widely discussed [172], is how hypoxia and the vasculature regulate macrophages
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and immune cells through HIFs and nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-kB) [192,193] and CXCR4 [194].
It cannot be established whether GSCs of perivascular and perinecrotic niches belong to the
same population, because, although showing the same stemness antigens, they still represent
progenitors that can be in different state of differentiation. The significance conferred to GSCs
in perinecrotic position as dedifferentiated tumor cells which reached stemness beyond a
certain point of dedifferentiation, cannot be recognized to GSCs in perivascular niches [45,189].
Letting aside the transdifferentiation of tumor cells into endothelial cells, which did not
received sufficient support, another point of link between the two microenvironments is
represented by cell migration through EMT that is promoted by hypoxia and bound to GSCs
[155]. GSCs can migrate along newly formed vessels and favor tumor diffusion.
The most important question in this topic is the occurrence of circumscribed necroses in the
tumor areas with the highest malignant phenotype including both avascular districts and
districts with a high vessel density, so that perinecrotic niches appear to be associated with
perivascular niches to characterize these malignant areas [45,189,195].
10. Conclusions
The origin of gliomas has been outlined as traceable back to the transformation of primitive
neuroepithelial cells or NSCs, capable of self-renewal and proliferation, i.e. endowed with
stemness properties, or to the dedifferentiation of adult glia to reach stemness properties. The
CSC responsibility for tumor proliferation, recurrence and resistance to therapies falls today
into the most credited hypothesis. Many experiments have shown that GSCs derive by
transformation of NSCs or they represent a simple functional stemness status. Some aspects
of the problem remain unresolved, for example, the relationship between TICs and CSCs or
the CSCs location in the tumor, as well as the existence in the tumor of NSCs that continuously
renew the CSCs quota.
Recently, a new concept arose to indicate everything in the tumor, outside cancer cells, that
regulates tumor proliferation, invasion, differentiation, resistance to therapies as the micro‐
environment, with its innumerable molecular pathways and numberless signalings and cross-
talks. Major expressions of the microenvironment are in GBM the perivascular and the
perinecrotic niches. The former are important for the endothelial cell/CSC relationship that,
on one side, maintains the stemness status of CSCs and, on the other side, gives origin to
angiogenesis. The latter are important for the occurrence of hypoxia through HIF-1/2 that can
induce CSC formation.
The neuropathological study of GBMs with the final goal to find a concrete expression to the
perinecrotic niche concept, provides an alternative interpretation to that considering perine‐
crotic CSCs as induced by hypoxia. They can be the remnants of CSCs that crowded the
hyperproliferating and malignant areas of the tumor in which necrosis developed for insuffi‐
cient vascularization. Perivascular niches are usually very well depicted as schemes that
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contemplate all the cells that can be in contact with vessels/endothelial cells. This event,
however, is not observed to be realized with all the identified cells in all the vessels, going from
capillaries or small vessels to larger vessels, MVPs or glomeruli in the different tumor areas.
The cells described in the schemes never occur concurrently in one or all the vessels, so that
the schemes themselves remain as a theoretical indication of possible relationships that can be
established between tumor cells and vessels as a consequence of a general molecular regulation
that is realized in the microenvironment.
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